Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml Publisher Pubmed



Mahalleh M1 ; Shabani M1, 2, 3 ; Rayzan E1, 2 ; Rezaei N2, 3, 4
Authors

Source: Immunotherapy Published:2019


Abstract

Recent therapeutic advances in cancer treatment recruit immune system potentiation against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either monotherapy or combination therapy, are investigating the impeding factors on the way of acute myeloid leukemia (AML) treatment. Due to the genetic diversity in AML progenitors, combining various strategies is more likely to be useful for improving patient outcomes. This review describes the details of applying monoclonal antibodies against AML, focusing on CD33, CD123, FLT3, CD45 and CD66 targeting. Furthermore, it clarifies the importance of immunotoxins, bispecific antibodies, chimeric antigen receptor (CAR)-T cells and T cell receptor-modified cells as reinforcing agents for monoclonal antibodies. © 2019 © 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
2. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)
3. Immunotherapy in Aml: A Brief Review on Emerging Strategies, Clinical and Translational Oncology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Amirhasan Zarnani (2)
Other Related Docs
4. Immunopathology and Immunotherapy of Myeloid Leukemia, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
5. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
6. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)
7. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
8. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
10. Investigation of Cebpa and Cebpa-As Genes Expression in Acute Myeloid Leukemia, Reports of Biochemistry and Molecular Biology (2019)
11. Programmable and Multi-Targeted Cars: A New Breakthrough in Cancer Car-T Cell Therapy, Clinical and Translational Oncology (2021)
12. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
13. Toll-Like Receptor 4 Signaling Pathway Is Correlated With Pathophysiological Characteristics of Aml Patients and Its Inhibition Using Tak-242 Suppresses Aml Cell Proliferation, International Immunopharmacology (2021)
14. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)
15. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
16. Dendritic Cell Vaccination Strategy for the Treatment of Acute Myeloid Leukemia: A Systematic Review, Cytotherapy (2024)
17. Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells, Cancer Medicine (2023)
18. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
19. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications, Frontiers in Immunology (2017)
20. Genetic, Hematologic and Psychological Aspects of Leukemia, Cancer Genetics and Psychotherapy (2017)